Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke – the ARAMIS trial
1. The ARAMIS trial revealed that the rate of favourable neurologic function at 90 days was 93.8% among patients assigned ...